Teva Pharma (TEVA) Reports In-Line Q1 EPS, Reaffirms Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Teva Pharma (TEVA) PT Lowered to $43 at Deutsche Bank
May 12, 2017 6:31 AM EDTDeutsche Bank lowered its price target on Teva Pharma (NYSE: TEVA) to $43.00 (from $45.00) while maintaining a Buy rating.
Analyst Gregg Gilbert noted TEVA reported decent 1Q results, with EPS upside driven by synergies and cost reductions that more than offset pressures... More
